Expertise in developing oral drug formulations for cancer therapies

With our dedication to improving the delivery and bioavailability of chemotherapy, we are open to discussing partnering opportunities either relating to our proprietary programs in clinical development or to our IV-to-oral technology.


From a corporate development perspective, we are well-positioned to collaborate with international pharmaceutical leaders, innovative early-staged companies, academic institutions and other research organizations to apply our proprietary technology to make a positive impact for cancer patients.



Modra Pharmaceuticals Announces Start of Phase II Study for its Lead Oral Chemotherapy in Patients with Metastatic Prostate Cancer
Read more

the IV to Oral switch

improving patient lives
Learn more


No current events
Read more